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DNA methylation changes could provide a
mechanism for DNA plasticity and dynamism for
short-term adaptation, enabling a type of cell
memory to register cellular history under differ-
ent environmental conditions. Some environ-
mental insults may also result in pathological
methylation with corresponding alteration of
gene expression patterns. Evidence from several
studies has suggested that in schizophrenia and
bipolar disorder, mRNA of the reelin gene (RELN),
which encodes a protein necessary for neuronal
migration, axonal branching, synaptogenesis,
and cell signaling, is severely reduced in post-
mortem brains. Therefore, we investigated the
methylation status of the RELN promoter region
in schizophrenic patients and normal controls as
a potential mechanism for down regulation of its
expression. Ten post-mortem frontal lobe brain
samples from male schizophrenic patients and
normal controls were obtained from the Harvard
Brain Tissue Resources Center. DNA was extrac-
ted using a standard phenol–chloroform DNA
extraction protocol. To evaluate differences be-
tween patients and controls, we applied methy-
lation specific PCR (MSP) using primers localized
to CpG islands flanking a potential cyclic AMP
response element (CRE) and a stimulating pro-
tein-1 (SP1) binding site located in the promoter
region. For each sample, DNA extraction, bisulfite
treatment, and MSP were independently repeated
at least four times to accurately determine the
methylation status of the target region. Forty-
three PCR trials were performed on the test and
control samples. MSP analysis of the RELN pro-
moter revealed an unmethylated signal in all
reactions (43 of 43) using DNA from the frontal
brain tissue, derived from either the schizophre-
nic patients or normal controls indicating that
this region of the RELN promoter is predomi-
nantly unmethylated. However, we observed a
distinct methylated signal in 73%of the trials (16of
22) in schizophrenic patients compared with 24%
(5 of 21) of controls. Thus, the hypermethylation of
the CpG islands flanking a CRE and SP1 binding
site observed at a significantly higher level
(t¼5.07, P¼0.001) may provide a mechanism
for the decreased RELN expression, frequently
observed in post-mortem brains of schizophrenic
patients. We also found an inverse relationship
between the level of DNA methylation using MSP
analysis and the expression of the RELN gene
using semi-quantitative RT-PCR. Despite the
small sample size, these studies indicate that
promoter hypermethylation of the RELN gene
could be a significant contributor in effecting
epigenetic alterations and provides a molecular
basis for the RELN gene hypoactivity
in schizophrenia. Further studies with a larger
sample set would be required to validate these
preliminary observations.  2005 Wiley-Liss, Inc.
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INTRODUCTION
A direct relationship between the environment and the
adaptation of genes resulting in altered gene expression
patterns has been well established [for a review see Abdolma-
leky et al., 2004]. In general, the inactive genes are legitimate
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candidates for silencing of gene expression due to DNA
methylation [Bird, 2002]. The addition of methyl groups to
the cytosine (C) of CpG dinucleotides is mediated by several
DNA methyltransferases in an interactive manner [Singal and
Ginder, 1999; Bestor, 2000; Kim et al., 2002]. In vertebrates,
although 4%–8% of cytosines [Attwood et al., 2002; Bird, 2002],
and 70% of all CpGs are methylated, less than 30% of
CpGs in the promoter regions of active genes are methylated
[Naveh-Many and Cedar, 1981; Kress et al., 2001]. There are
about 29,000 CpG islands in the human genome [Costello and
Plass, 2001] and 50%–60% of genes contain CpG islands that
regulate the gene’s activity depending upon their state of
methylation [Singal and Ginder, 1999]. Despite the main-
tenance of a specific pattern of DNA methylation throughout
cell divisions, it may become altered due to global or local
demethylation and de novo methylation [Kress et al., 2001].
The activity of methyltransferase enzymes, and the presence
of folic acid and S-adenosyl methionine are necessary com-
ponents in de novo methylation [Kim, 2000]. Any imbalance
in the levels, or activity, of these components may cause
developmental defects or cell death due to aberrant DNA
methylation changes [Watson and Goodman, 2002]. Addition-
ally, several animal studies suggest that the epigenetic germ-
line DNA modifications and cytosine methylation patterns are
inherited [Russo et al., 1996; Roemer et al., 1997; Wolff et al.,
1998; Cooney et al., 2002].
The methylation rate of CpG sites is determined by the
proportional availability of DNA methyl transferases (DNMT)
and other factors, and their relative affinity for a given CpG site
on the DNA [Russo et al., 1996]. Cytosine methylation can
mediate silencing of gene expression through the actions of
proteins such as MeCP2, MBD1, MBD2, MBD3, and MBD4,
which bind directly to methylated DNA and/or through other
factors that bind directly or indirectly to methylated CpGs.
This binding inhibits transcription from these sites due to the
establishment of a silenced histone code [Hendrich et al., 1999;
Attwood et al., 2002; Bird, 2002; Thiagalingam et al., 2003].
Thus, the amount and the specific sites of DNA methylation
directly correlates with gene expression in specific cells at
specific times [Ngo et al., 1996; Russo et al., 1996; Kress et al.,
2001; Kim et al., 2002].
Interestingly, some nutritional derivatives such as butyrate
(one of milk products) through inhibition of histone deacety-
lases [Zhu and Otterson, 2003], or tea polyphenol (-)-epigallo-
catechin-3-gallate that inhibits DNMT [Fang et al., 2003] may
also influence genes DNA methylation level. Additionally,
there is accumulating evidence that suggests that the activa-
tion of genes may have a feedback effect impacting DNA
methylation patterns. In a recent animal study, neuronal
depolarization reduced the methylation level of the BDNF
gene, dissociated MeCP2 from the promoter region, and
increased BDNF gene transcription [Martinowich et al., 2003].
Although, in general, dense methylation results in irrever-
sible silencing of gene expression, strong activators may
overcome partial methylation. Suspension of the process of
DNA methylation, due to the direct effect of transcription
factors involved in gene activation, has been reported [Kress
et al., 2001; Bird, 2002]. Successive binding of transcription
factors to a gene’s regulatory region may alter the nucleosome
structure leading to decreases in the methylation rate and
retention of the capability for gene expression for a prolonged
period of time [Murray et al., 2000]. For example, in rat liver,
glucocorticoid induces DNA demethylation in the tyrosine
aminotransferase gene that is stable after hormone with-
drawal and chromatin remodeling. Subsequent hormonal
stimulation evokes a much stronger response by the gene,
suggesting a potential mechanism for cell memory [Thomassin
et al., 2001]. Thus, incremental differential DNA methylation
of the genome could play a critical role in allowing DNA
plasticity, enabling gradual adaptation to variable environ-
ments in each generation. Thus, adaptation to the environ-
ment may occur at the individual level due to DNA methylation
changes in response to specific environments, and at the
species level due to natural selection [Monk, 1995]. By the
same token, these findings also suggest that environmental
factors, by altering methylation states of genes, may partici-
pate in the pathogenesis of multi-factorial diseases, and that
epigenetic modification may play a role in schizophrenia and
other neuronal/ brain disorders [Costa et al., 2001].
Reelin, an extra-cellular matrix protein mainly expressed by
GABAergic inter-neurons, binds to lipoprotein receptors
and activates a tyrosine kinase cascade leading to Dab 1
phosphorylation [Pesold et al., 1999]. These signaling events
are essential for neuronal migration, axonal branching, and
synaptogenesis throughout brain development. Additionally,
reelin activates a second-messenger cascade that influences
gene expression required for long-lasting structural changes
in the neurons [Pesold et al., 1999]. The reelin gene (RELN)
localizes to chromosome 7, and harbors a long CpG rich
promoter region [DeSilva et al., 1997]. Bisulfite treated DNA
sequencing in the NT2 neuronal precursor cell line to analyze
the effects of demethylating agents demonstrated that DNA
methylation of theRELN promoter region could be responsible
for silencing RELN gene expression [Chen et al., 2002].
Because the mRNA and protein levels of reelin are severely
reduced in post-mortem brains of schizophrenia and bipolar
patients, some investigators have hypothesized that reduced
reelin levels may increase susceptibility to these disorders
[Fatemi et al., 2000; Costa et al., 2001]. Therefore, we decided
to investigate whether there is a direct relationship between
differential promoter methylation of the RELN gene and
schizophrenia, by comparing the methylation status of brain
samples from patients who had been diagnosed with schizo-
phrenia to samples from controls.
MATERIALS AND METHODS
Patient and Control Samples
Five post-mortem brain samples from male patients with
schizophrenia and five male normal controls of the same age at
similar post-mortem interval were obtained from the Harvard
brain tissue resources center. All ten donors were between the
age of 42 and 50 years, as shown in Table I. Autopsies were
carried out between 14 and 29 hr after death. Brain tissues
were stored at 808C until further analysis.
DNA Extraction
The post-mortem brain tissue was dissected to obtain pure
gray matter through removal of the pia, visible blood vessels,
and white matter. DNA was extracted using a standard
phenol–chloroform DNA extraction protocol.
Bisulfite Treatment
For the MSP assay, genomic DNA was isolated from the brain
samples and subjected to bisulfite modification. Bisulfite treat-
ment converts unmethylated cytosine nucleotides to uracils,
while methylated cytosine nucleotides remains unchanged
[Frommer et al., 1992; Herman et al., 1996; Singal and Ginder,
1999]. In brief, approximately 1mg of genomic DNA was
denatured with 2M NaOH for 15 min, followed by bisulfite
treatment with freshly prepared 10 mM hydroquinone and 3M
sodium bisulfite, pH 5.0 (Sigma, St. Louis, MO). Each reaction
was overlaid with mineral oil and incubated at 508C for 16–20 hr.
After treatment, the modified DNA was purified using a Wizard
DNA purification kit (Promega, Madison, WI), followed by
desulfonation treatment with 3M NaOH, which changes uracil
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to thymine (T). The DNA was ethanol precipitated, and the
purified DNA pellet was resuspended in 30 ml of distilled water.
Sequencing of Bisulfite Treated DNA
The primers used for the amplification of the RELN
promoter region from the bisulfite modified genomic DNA
were as follows. The forward primer: 50-GTATTTTTTTAG-
GAAAAATAGGGTATATTGA-30 (687 to 656) and the
reverse primer: 50-ACTCCCAAAATTACTTTAAACC-30 (180
to202). The PCR product was sequenced using the following
nested primer: 50-GTTAAAGGGGTTGGTTTTT-30 (659 to
640).
Methylation Specific PCR (MSP) Primer Design
MSP was used to determine the differences in the DNA
methylation status [Herman et al., 1996] of the RELN
promoter region, between the patients and controls. The
sequences of the forward and reverse MSP primers to
distinguish between the methylated (M) and unmethylated
(U) genomic DNA in the RELN promoter used in this study
were as follows: methylated DNA specific primers: forward
primer: 50-CGGGGTTTTGACGTTTTTCG-30 (602 to 582),
reverse primer: 50-CGCCCTCTCGAACTAACTCGACG-30 (418
to441). Unmethylated DNA specific primers: forward primer:
50-GTGGGGTTTTGATGTTTTTTG-30 (603 to 582), reverse
primer: 50-CACCCTCTCAAACTAACTCAACA-30 (418 to
441). The site corresponding to the forward primer included
a putative cyclic AMP response element (CRE), TGACGT,
which when methylated has been shown to reduce gene
expression in several genes [Moens et al., 1993]. On the other
hand, the reverse primer included a core sequence of a putative
stimulating protein-1 (SP1) binding site (GGCGGG).
MSP-PCR Setup and Cycling Conditions
The PCR reaction was performed in a total volume of 25 ml,
consisting of the following components: 2.5 ml of 10 buffer
(670 mM Tris-HCl, pH 8.8, 166 mM ammonium sulfate, 67 mM
magnesium chloride, 10 mMb-mercaptoethanol), 0.4ml of 10mM
dNTPs (Invitrogen, Carlsbad, CA), 1.5ml of dimethyl sulphoxide
(Sigma), 2.5 U of platinium Taq DNA polymerase (Invitrogen),
25 pmol each of methylated specific or unmethylated specific
primers, and 50 ng bisulfite modified genomic DNA.
Bisulfite modified placental DNA (PD) and in vitro methy-
lated DNA (ID) was used as negative and positive controls,
respectively. In addition, water blanks were used as a control
for the PCR reactions to detect any potential contamination
events.
PCR cycling conditions were as follows: one cycle each of
948C for 2 min, 608C for 1 min, 708C for 1 min, 31 cycles of 948C
for 30 sec, 608C for 40 sec, 708C for 40 sec, followed by a final
extension at 708C for 10 min. A 10 ml sample of each PCR
product was analyzed by electrophoresis on a non-denaturing
6% polyacrylamide gel, stained with ethidium bromide, and
visualized under UV light.
Recognizing that the conditions of the bisulfite treatment,
and the location of the cells from the original tissue blocks,
could have confounding effects on the pattern of methylation
detected we repeated the DNA extraction, bisulfite treatment,
and PCR for each of the samples analyzed in this study at least
four times. In summary, we performed 21 trials for controls and
22 trials for patients as shown in Table II.
TABLE I. Summary of Selected Clinical and Demographic Data of the Controls and Patients
Brain sample no. Group Sex Age (years)
Post-mortem
interval (hr)
Brodmann’s
area (BA)
Laterality: left/center
frontal lobe
1 Control Male 50 26.50 BA 10 Right
2 Control Male 44 23.00 BA 9 Right
3 Control Male 46 25.90 BA 10 Left
4 Control Male 47 18.80 BA 10 Left
5 Control Male 43 23.00 BA 9 Left
Average (SD) 46 (2.74) 23.44 (3.05)
6 Schizophrenia Male 44 17.80 BA 10 Left
7 Schizophrenia Male 42 14.20 BA 10/9 Right
8 Schizophrenia Male 46 29.06 BA 10 Left
9 Schizophrenia Male 46 29.50 BA 10 Right
10 Schizophrenia Male 49 24.50 BA 10 Left
Average (SD) 45.4 (2.61) 23.01 (6.81)
TABLE II. Frequency of Methylated/Unmethylated Signals During MSP Analysis of the Samples From Controls and
Schizophrenic Patients
Sample no. Group No. of trials
No. of negative
methylated signals
No. of positive
methylated signals
Percent of positive
methylated signals
1 Control 4 2 2 50
2 Control 4 3 1 25
3 Control 4 4 0 0
4 Control 5 4 1 20
5 Control 4 3 1 25
Average (SD) 4.2 (0.45) 3.2 1 (0.71) 24 (0.18)
6 Schizophrenia 4 1 3 75
7 Schizophrenia 5 1 4 80
8 Schizophrenia 4 1 3 75
9 Schizophrenia 5 2 3 60
10 Schizophrenia 4 1 3 75
Average (SD) 4.4 (0.55) 1.2 3.2 (0.84) 73 (0.55)
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Analysis of RELN Expression Using
Semi-Quantitative RT-PCR
Total RNA was prepared from brain samples, using TRIzol
(Life Technologies, Inc., Grand Island, NY) according to
manufacturer instructions. We also used total RNA from
several human tissues obtained through Clontech to set up the
accurate conditions for further experiments (Fig. 1). cDNA
synthesis and PCR amplification was performed essentially as
previously described [Cheng et al., 2004].
The gene specific primer pair used in the analysis of the
RELN gene expression are as follows: forward primer, 50-
CGGCATGGAGCGCAGTGGCTGGGC-30 located in exon 1 and
reverse primer, 50-GTGTATAGTCCTGTCACCAGCAAGC-30
located in exon 2 of the variant 1 RELN. The b-actin gene was
used as an internal standard to normalize the abundance of the
RT-PCR product derived from the RELN gene [Cheng et al.,
2004]. Note that the extracted RNA from the tissue of seven
brains was qualified for RT-PCR.
Data Analysis
A t-test was used to compare the arcsine of the proportion of
trials that showed methylation in the case and control groups.
The Cochran test for the equality of variances showed that
the variance for the proportion of trials that were methylated
in the cases was not different from the variance in the controls
(F¼ 1.90, P¼ 0.55). This allowed us to proceed with the pooled
variance test using all of the available data in this small
sample.
RESULTS
We surveyed the expression of RELN in different human
tissues using semi-quantitative RT-PCR (Fig. 1). The level of
expression was highest in the brain followed by breast, liver,
stomach, kidney, and lung in our experiment. We considered
the possibility that down regulation of RELN expression in
the schizophrenia patients could be correlated to promoter
methylation. We evaluated the methylation status of the
RELN promoter by both bisulfite modified DNA sequencing
and MSP analysis using the genomic DNA focusing at the
sequences around the CRE and the SP1 elements.
The level of methylation of the C residues in the CpG islands
determined from the MSP analysis showed direct concordance
with the relative heights of the DNA sequencing traces derived
from the C and T residues (Fig. 2). These results suggested that
the high throughput MSP analysis could be used to determine
the level of methylation of theRELN promoter. The expression
patterns of these samples also showed concordance with
methylation status of the RELN promoter determined by both
DNA sequencing and the MSP analysis (Figs. 2–4). Thus, we
analyzed and compared the levels ofRELN promoter methyla-
tion in samples from the schizophrenia patients and matched
Fig. 1. Differential expression of RELN in various normal human
tissues. Lanes 1–9 correspond to samples from lung, liver, stomach, kidney,
heart, breast, bone marrow, colon, and brain tissues, respectively. RT-PCR
analysis of the RELN expression was normalized with the levels of b-actin
from the same samples.
Fig. 2. Bisulfite modified DNA sequencing of the RELN promoter in
schizophrenia patients and controls. At the top of the figure, the unmodified
genomic DNA sequence and the bisulfite modified DNA sequence (methy-
lated) of the promoter region corresponding to 595 to 520 at a CRE
binding site and its down stream region is shown. Underlined Cs in the CpGs
are candidates for methylation. Panels A, B, and C show the sequence
traces and the corresponding MSP analyses data for the unmethylated
(UM), partially methylated (PM), and highly methylated (HM) templates,
respectively. Panel D shows the sequence traces of three successive SP1
binding sites (420 to 398) derived from a control (left; template from
sample shown in panel A) and a patient (right; template from sample shown
in panel B). U and M indicate the use of primers that amplify unmethylated
and methylated DNA templates. In the sequence traces red, black, blue, and
green indicate T, G, C, and A, respectively. When the template was
methylated, most of the Cs in CpGs gave a blue trace as opposed to a red trace
indicating the conversion of C to T. [Color figure can be viewed in the online
issue, which is available at www.interscience.wiley.com.]
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controls using the MSP analysis. Our results consist of ten
observations with a maximum of five measures of methylation
each. Table I shows the sample composition. All subjects were
male. There were no significant differences between the case
and control groups with respect to age, post-mortem interval,
or number of trials (Table I). Table II shows the data for each
subject.
From 22 trials for patients, we obtained 16 methylated
signals (73%). In contrast, from 21 trials for controls we found
five methylated signals (24%). The pooled t-test showed that
the samples from brains of schizophrenic subjects were signi-
ficantly more likely to be methylated than those of the control
subjects (t¼5.07, P¼ 0.001) (Table III and Fig. 3).
Furthermore, the expression pattern of the RELN gene in
selected samples, as determined using semi-quantitative RT-
PCR, also exhibited a high level of concordance to the degree of
methylation determined by the MSP analysis (Fig. 4).
DISCUSSION
From an etiological point of view, there is strong evidence to
suggest that both L-methionine as well as environmental
insults can induce pathologic DNA hypermethylation, which
silences gene expression. It is known that transient ischemia
increases DNA methylation and endangers the survival of CNS
neurons, and that prevention of DNA methylation prevents
brain damage [Endres et al., 2000]. Since ‘‘Fetal hypoxia is
associated with greater structural brain abnormality among
schizophrenic patients and their non-schizophrenic siblings
than controls’’ [Cannon et al., 2002], DNA methylation pro-
cessing may be abnormal in schizophrenic patients and their
family members. Nitric oxide (NO), which is believed to play
a role in schizophrenia, has neurodegenerative effects in
focal ischemia and could also be a mediator of pathological
hypermethylation [Hmadcha et al., 1999].
In an intriguing connection to psychiatric diseases, severely
reduced mRNA and protein levels of reelin was seen in the
examination of post-mortem brains from schizophrenia and
bipolar disorder patients [Fatemi et al., 2000; Costa et al.,
2001]. A recent study reported an over-expression of DNMT1
(an enzyme that primarily acts to maintain DNA methylation
states) in the GABAergic interneurons of schizophrenic
patients assayed by RNA in situ hybridization [Veldic et al.,
2004]. Concurrent with DNMT1 over-expression, the RELN
mRNA was reduced in the same layers of BA 10 in schizo-
phrenic patients [Veldic et al., 2004]. Studies using animal
models and cells in culture also showed that the expression of
reelin is influenced by methylation of the RELN promoter
region [Chen et al., 2002]. Furthermore, L-methionine, a
known methyl donor is also known to increase the amount of
cytosine methylation in the CpG islands of theRELN promoter
region resulting in a decrease in the reelin mRNA levels that
may exacerbate symptoms in most schizophrenic patients
[Tremolizzo et al., 2002].
We have followed up on these important observations and
report for the first time that brain samples from patients who
had been diagnosed with schizophrenia show increased DNA
methylation of the CpG islands localized to theRELNpromoter
regulatory regions. In this study, first we confirmed the
reliability of the use of a high throughput MSP assay for
determining the methylation status of the RELN promoter
(Fig. 2). We used MSP analysis to evaluate the methylation
status of the RELN promoter and show that there is a
significantly higher level of the methylation of the RELN
promoter region in brain samples from patients who had been
diagnosed with schizophrenia when compared to the matched
controls (Fig. 3 and Tables I–III). The expression of the RELN
gene in the samples analyzed also exhibited a high level of
concordance to the degree of DNA methylation suggesting that
promoter methylation is responsible for silencing of RELN
Fig. 3. MSP analysis of the CpG islands of the promoter of the RELN gene in the indicated brain samples from schizophrenic patients and controls. In
vitro methylated DNA (ID) and placental DNA (PD) serve as positive and negative controls, respectively. Genomic DNA (GD) serves as an additional control
to indicate that the same primers will not amplify the unmodified DNA. Water (H2O) was used to detect contamination. Lanes U and M indicate the presence
of unmethylated and methylated template, respectively.
Fig. 4. Analysis of RELN expression in schizophrenia. A: Total RNA
prepared from indicated post-mortem brain samples and analyzed by semi-
quantitative RT-PCR (Lanes 1–7). Lanes 1–3 and 4–7 correspond to
normal and patient brains, respectively. Multiplex RT-PCR analysis for b-
actin (upper band) and RELN (lower band), respectively as described under
Methods. B: Lanes 1–3, samples with decreasing level of methylation
(lower panel) with corresponding increase in the level ofRELN expression
(upper panel: upper band, b-actin; lower band, RELN RT-PCR product).
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expression in schizophrenia (Figs. 3 and 4). The MSP analysis
used in our studies considered CpG methylation in a putative
c-AMP response element localized to theRELN gene promoter
region. Interestingly, it has also been previously reported that
methylation of the c-AMP response element in the promoter
region of genes could cause a decrease in the level of gene
expression [Moens et al., 1993].
Our control and patient samples were matched for age, sex,
race, and post-mortem interval to reduce the likelihood that
these variables would confound our analyses. Furthermore,
our review of medical records showed that the patients had not
used any drugs known to change DNA methylation status,
at least in the last eight weeks of their lives. Thus, it is
reasonable to predict that the useful effects of sodium valproate
in schizophrenia and bipolar disorder could be due to its
inhibition of the histone deacetylases, which ultimately results
in the removal of the methyl groups from the methylated
cytosine of the DNA [Alonso-Aperte et al., 1999; Manev and Uz,
2002; Tremolizzo et al., 2002]. Given our small sample size, it is
possible that our results are an artifact of some unknown
confound. Thus, replication of these findings in a larger sample
set will be required to verify whether the DNA methylation of
the putative CRE and SP1 binding sites in the RELN gene
promoter are responsible for gene silencing in the frontal lobe
of schizophrenic patients.
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